finance
OraSure Forecasts Q2 Revenue Between $27 Million and $30 Million
OraSure Technologies provided its revenue outlook for the second quarter of 2026 during its first-quarter earnings call. The company also discussed plans for margin expansion, near-shoring manufacturing to Africa, and upcoming FDA submissions targeted for mid-2026. OraSure anticipates clearances for its CT/NG test and Colli-Pee device in the middle of the year.
May 6, 11:42 PM·1m read1 source
entrepreneur.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
OraSure Technologies reported its first-quarter 2026 financial results and issued guidance for the current quarter. The company expects second-quarter revenue in the range of $27 million to $30 million. During the earnings call, OraSure outlined several operational priorities.
These include continued focus on margin expansion and efforts to near-shore manufacturing activities in Africa. The company said it is targeting midyear FDA clearances for two products. The first is a CT/NG test, and the second is the Colli-Pee device.
OraSure anticipates that these regulatory milestones could occur around the middle of 2026. The clearances would apply to the company's diagnostic offerings. The earnings call summary highlighted these elements as key points for investors.
No specific first-quarter revenue or earnings figures were detailed in the available summary.
